The efficacy and safety of keverprazan, a novel potassium‐competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double‐blind multicentre study
Alimentary Pharmacology & Therapeutics2022Vol. 55(12), pp. 1524–1533
Citations Over TimeTop 10% of 2022 papers
Songfeng Chen, Deliang Liu, Honghui Chen, Aijun Liao, Fangfang Li, Chengxia Liu, Xing Li, Shengbao Li, Yan Zhang, Yang Wang, Min Xia, Qinghong Guo, Xin-Pu Miao, Zhili Wen, Min Xu, Yin Hekun, Huixin Chen, Minhu Chen, Ying Xiao
Abstract
This study demonstrated the non-inferior efficacy of keverprazan to lansoprazole in treating EO. The incidences of drug-related AEs were comparable between keverprazan and lansoprazole.
Related Papers
- → Interleucinas na encefalopatia hipóxico-isquêmica(2003)14 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)